secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intra-Cellular Therapies, Inc. (—)
CIK:        0001567514
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001193125-25-071325
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

J&J completes $14.6B acquisition of Intra-Cellular Therapies at $132/share
--------------------------------------------------------------------------

- Each ITCI share converted into right to receive $132.00 in cash, no interest.
- Total consideration ~$14.6 billion, funded by Johnson & Johnson cash-on-hand.
- ITCI common stock to be delisted from Nasdaq; Form 25 filed, Form 15 to follow.
- All pre-Merger directors resigned; J&J-appointed directors now govern the Company.
- Certificate of incorporation and bylaws amended and restated at Effective Time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567514/000119312525071325/0001193125-25-071325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567514/000119312525071325/d928406d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-071325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer